Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated. The Big Pharma and Mid Pharma peer sets are an integral part of development and have been furthering efforts via deal-making. The peer groups signed more than 300 immuno-oncology deals between 2012 and 2016, growing at a compound annual growth rate of 48%. Aggregate deal value over this period was $48bn.

This Datamonitor Healthcare report contains a Strategy module.